Francesco Novelli

1986-1988 Tecnhogenetics s.p.a. Laboratories , S. Mauro T.se; Responsible of monoclonal antibody production; 

1993-1994 Visiting scientist at Wistar Institute, Philadelphia 

1995 Visiting scientist at Cell Growth Regulation’s Laboratory, King’s College London

 1996-2002 Assistant Professor, University of Turin, Dept. of Clinical and Biol. Sciences, Lab of Immunol, Orbassano, Italy 

2001- 2002 Visiting Professor, Laboratory of Human Genetics of Infectious Diseases, Enfants Malades Medical School, Paris, France

2002-today Director of Centro Ricerche in Medicina Sperimentale, Laboratory of Tumor Immunology Città della Salute e della Scienza di Torino 

2006-2016 Associate Professor of Immunology (MED/04), Medical School, University of Torino, Università di Torino 

2010-today Responsible of the Cellular Immunology Unit of the Immunology Transplantation Department of the Azienda Ospedaliera-Universitaria Città della Salute e della Scienza di Torino 

2014-today Shareholder of NatiMab Therapeutics srl, Colleretto Giacosa (Torino) 

2015-today Member of Molecular Biotechnology Centre, University of Turin 

2016-today Full Professor of Immunology (MED/04), University of Turin, Dept. of Molecular Biotechnology and Healthy Science 

2017-today Chair of PhD Program in Molecular Medicine, University of Turin 

2018-2024 Director of the Department of Molecular Biotechnology and Health Sciences, University of Turin

Master Degree, Biological Sciences, University of Turin, Turin, 1984 

NA (research training), Microbiology, University of Turin, Turin, 1988-1993 

NA (research training), Cytokine/Interferon signaling, Research Unit Hoffmann La Roche, Basel, Switzerland, 1988-1989 

PhD, Physiopathology, University of L’Aquila, L’Aquila, 1993

2018: Italian Association for Cancer Research (AIRC)(IG 19931): “Combination of chemotherapy and immunotherapy as new paradigm to cure pancreatic cancer “ Euro 523000 (five years) 

2022: Piano Nazionale Di Ripresa E Resilienza (PNRR) missione 6 (PNRR-POC-2022-12375658): “A next generation DNA vaccine coding for immunodominant sequences of alpha-enolase to cure pancreatic cancer”, 950000 (two years) 

2023: AIRC (IG 27020): “Toward a novel precision chemo-immune therapy to cure pancreatic cancer” Euro 589270 (five years) 

2023: PRIN 2022ELLA9L: “Combination of IDO-P3Kgd axis inhibition and tumor associated antigens DNA vaccination to cure pancreatic cancer” Euro 245236 (two years). 

1988: Winner of National Exam for ENI-Sclavo fellowship in cancer research; 

1990: Winner of National Exam for AIDS research fellowship by Istituto Superiore di Sanità; 

2004: Winner of Author Prize-Cytokine & Growth Factor Reviews (Elsevier) Most Down-loaded review; 

2013: Winner of Author Prize FEBS letter, Most Down-loaded review; 

2014: National Habilitation as Full professor of General Pathology(MED/04)

Ribovax Biotechnologies, SA (CH), Bioline Diagnostici srl (IT). Novelli F, Tomaino B, Cappello P. Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma. WO/2008/037792A1; 

NatiMab Therapeutics srl, F. Novelli, B.Tomaino, P. Cappello. A HUMAN Alpha-enolase derived-monophosphorylated peptide useful for diagnosis and treatment of pancreatic adenocarcinoma and for generate antibodies to the above mentioned mophosphorylarted peptide and their uses; WO2011030302; 

NatiMab Therapeutics srl, F. Novelli, M. Capello, P. Cappello. A method and a kit for the in vitro diagnosis of pancreatic ductal adenocarcinoma or for determining the predisposition to pancreatic ductal adenocarcinoma WO 2013186748 A1. 

University of Turin, Italy; F. Novelli, P. Cappello, C. Curcio, S. Brugiapaglia. A DNA vaccine for use in the therapeutic and /or prophylactic treatment of tumor diseases; PCT E141583.